TY - JOUR T1 - Pravastatin was not better than usual care in reducing all cause mortality or CHD events JF - Evidence Based Medicine JO - Evid Based Med SP - 106 LP - 106 DO - 10.1136/ebm.8.4.106 VL - 8 IS - 4 A2 - , Y1 - 2003/07/01 UR - http://ebm.bmj.com/content/8/4/106.abstract N2 - (2002) JAMA 288, 2998. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care.. ;. :. –3007.OpenUrlCrossRefPubMedWeb of Science
 
 QUESTION: In older patients with well controlled hypertension and moderately elevated low density lipoprotein cholesterol (LDL-C), is pravastatin better than usual care in reducing all cause mortality and coronary heart disease (CHD) events? Randomised (allocation concealed*), unblinded,* controlled trial with mean 4.8 years of follow up (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT-LLT]). 513 clinical centres in the US, Canada, Puerto Rico, and the US Virgin Islands. 10 355 patients (mean age 66 y, 51% men) who were enrolled in the ALLHAT (age ≥55 y and stage 1 or 2 hypertension with ≥1 additional risk factor for CHD; fasting LDL-C concentration 3.1–4.9 mmol/l for those with no known CHD, or 2.6–3.3 mmol/l for those with known … ER -